Long-term efficacy and tolerability of pentosan polysulphate sodium in the treatment of bladder pain syndrome
DOI:
https://doi.org/10.5489/cuaj.597Abstract
Objective: The primary objective of this study is to report on the
long-term efficacy and tolerability of pentosan polysulphate sodium
(PPS) in patients with bladder pain syndrome (BPS). The secondary
objective is to find the predictors of the long-term outcome.
Methods: This is a single institution, retrospective study. The study
period was from 1994 to 2008. All patients fulfilled the clinical
criteria of BPS, as suggested by European Society for the Study of
Interstitial Cystitis. We included only patients with de novo BPS
diagnosis and no previous PPS or other treatment. The efficacy
of PPS was measured with the global response assessment scale
(GRA). Patients were stratified into 2 groups based on the duration
of the treatment. Group 1 took the drug for less than 12 months.
Group 2 took the drug for more than 12 months.
Results: There were 271 patients eligible for the study. Most of the
patients were female (90%), with the mean age at presentation of
45.5 years. The average duration of symptoms was 28.5 months.
The mean follow-up was 22 months (range 3-130). Out of all the
patients, 147 patients (54.2%) reported over 50% improvement
using the GRA. The reported efficacy was higher in Group 2 (60%).
Ninety-three patients (34.3%) decided to stop taking the medication
for various reasons. The most common reasons to stop the
medication were poor outcome (16.6% of patients) and side effects
(11.1% of patients). Poor outcome was associated with nocturia,
smoking and detrusor overactivity. Good outcome was associated
with longer PPS intake (>12 months) and severe cystoscopic findings
of glomerulation.
Conclusion: Pentosan polysulphate sodium is an effective oral
therapy to control the symptoms of BPS with good long-term efficacy
and tolerability.
Downloads
Downloads
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.
